Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on BGMD, CPST, ENOC and STSI Issued by the Paragon Report

BGMD
Free Research Reports on BGMD, CPST, ENOC and STSI Issued by the Paragon Report

NEW YORK, NY -- (Marketwired) -- 05/29/13 -- The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

BG Medicine, Inc. (NASDAQ: BGMD) shares spiked 13.37 percent on volume of 1.73 million shares traded Tuesday to close at $1.95. The company announced that it has presented new clinical research data on the BGM Galectin-3 test in heart disease at the 2013 European Society of Cardiology Heart Failure Congress.

Find out more about BG Medicine including full access to the free equity report at: www.ParagonReport.com/BGMD

Capstone Turbine Corporation (NASDAQ: CPST) shares surged 13.59 percent on volume of 18.51 million shares traded Tuesday to close at $1.17. The company announced that it has a major order from a prominent privately held real estate and investment firm. Shares of Capstone Turbine have gained approximately 31 year-to-date.

Find out more about Capstone Turbine including full access to the free equity report at: www.ParagonReport.com/CPST

EnerNOC, Inc. (NASDAQ: ENOC) shares declined 15.86 percent on volume of 2.14 million shares traded Tuesday to close at $15.01. Credit Suisse has recently downgraded the company's rating to "neutral" from "outperform" Shares of EnerNOC have gained approximately 28 percent year-to-date.

Find out more about EnerNOC including full access to the free equity report at: www.ParagonReport.com/ENOC

Star Scientific, Inc. (NASDAQ: STSI) shares traded in the range of $1.43 to $1.62 before settling at $1.60 a share Tuesday, an increase of 11.89 percent. The company reported net sales of $2.5 million for the first quarter of 2013, an increase of 127 percent when compared to the year ago quarter.

Find out more about Star Scientific including full access to the free equity report at: www.ParagonReport.com/STSI

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.